Kurze Synopsis der Behandlung von Nebenwirkungen und Leitsymptomen unter medikamentöser Tumortherapie mit komplementärmedizinischen Maßnahmen

Zusammenfassung

Die medikamentöse Tumortherapie umfasst Behandlungsformen wie die klassischen Zytostatika, neuere Substanzen wie monoklonale Antikörper und Tyrosinkinasehemmer, sowie die aktuellsten Innovationen, die sogenannten Checkpointinhibitoren. Dieses therapeutische Repertoire erlaubt eine immer gezieltere, teilweise auch individuelle, differenzierte und effektive Behandlung vieler Tumorerkrankungen. Aber nicht nur der ökonomische Preis erscheint uns oft unverhältnismäßig hoch. Die mit den genannten Medikamentenklassen potenziell einhergehenden Nebenwirkungen oder „Adverse Effects“ sind auch bei den neueren Substanzen relevant und fügen sich in das bekannte Spektrum der Symptome ein. Umso bedeutender ist der gezielte und möglichst effektive Einsatz supportiver Therapiemaßnahmen. Hier können bewährte und neuere Behandlungsmethoden aus den Bereichen Naturheilverfahren, Erfahrungsmedizin und Komplementärmedizin wertvolle Ergänzungen bieten.

Summary

Medical tumor therapy includes forms of treatment with classic chemotherapy, new other specific therapy forms such as tyrosine kinase inhibitors, monoclonal antibodies and latest innovation, the so called checkpoint inhibitors. This therapeutic repertoire allows a more targeted, individualized and effective tumor treatment. But not only the economic costs of those treatments appear often disproportionate to us. The adverse treatment effects associated with these forms of tumor therapy are also relevant with the new substances are found in the well-known spectrum of side effects. Therefore the selective and effective use of supportive care is of great importance. At this point proven and up to date treatment methods from naturopathy, experience medicine and complementary medicine may offer valuable addition to the standard treatments.

Schlüsselwörter

Chemotherapie - Nebenwirkungen - Komplementärmedizin - Naturheilverfahren - supportive Therapie

Keywords

chemotherapy - adverse effects - side effects - complementary medicine - naturopathy - supportive therapy

• Literatur

• 1 Addington J, Freimer M. Chemotherapy-induced peripheral neuropathy: an update on the current understanding. F1000Research 2016; 5 F1000 Faculty Rev-1466
• 2 Bittenbring JT, Neumann F, Altmann B, Achenbach B et al. Vitamin D deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B-cell lymphoma treated with but not without rituximab. J Clin Oncol 2014; 32(29): 3242-8
• 3 Carlson BA, Yoo MH, Shrimali RK, Irons R, Gladyshev VN, Hatfield DL, Park JM. Role of selenium-containing proteins in T-cell and macrophage function. Proc Nutr Soc 2010; 69(3): 300-10
• 4 Carr AC, Vissers MC, Cook JS. The effect of intravenous vitamin C on cancer- and chemotherapy-related fatigue and quality of life. Front Oncol 2014; 4: 283
• 5 Cheng XL, Liu HQ, Wang Q, Huo JG, Wang XN, Cao P. Chemotherapy-induced peripheral neurotoxicity and complementary and alternative medicines: progress and perspective. Front Pharmacol 2015; 6: 234
• 6 Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Lapin J, Portenoy RK, Esteban-Cruciani N. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage 2009; 37(4): 622-31
• 7 Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, Gasche C. Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 2014; 9(4): e94217
• 8 Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12(5): 489-95
• 9 Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, Macciò A, Mantovani G. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 2006; 22(2): 136-45
• 10 Gröber U. Arzneimittel und Mikronährstoffe. Stuttgart: Wissenschaftliche Verlagsgesellschaft; 2014
• 11 Gröber U, Holzhauer P, Kisters K, Holick MF, Adamietz IA. Micronutrients in oncological intervention. Nutrients 2016; 8(3): 163
• 12 Heo YS, Chang HM, Kim TW, Ryu MH, Ahn JH, Kim SB, Lee JS, Kim WK, Cho HK, Kang YK. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol 2004; 44(10): 1166-72
• 13 Holzhauer P, Koula-Jenik H, Pempelfort K, Schneider B. Prophylaxe der Chemotherapie assoziierten oralen Mukositis. Dtsch Z Onkol 2015; 47: 36-40
• 14 Hong R. The thymus. Finally getting some respect. Chest Surg Clin N Am 2001; 11(2): 295-310
• 15 Khasabova IA, Khasabov S, Paz J, Harding-Rose C, Simone DA, Seybold VS. Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy. J Neurosci 2012; 32(20): 7091-101
• 16 Klauke AL, Racz I, Pradier B, Markert A, Zimmer AM, Gertsch J, Zimmer A. The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol 2014; 24(4): 608-20
• 17 Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, Schütte K et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. Nutr J 2012; 11: 52
• 18 Moretti S, Oikonomou V, Garaci E, Romani L. Thymosin α1: burying secrets in the thymus. Expert Opin Biol Ther 2015; 15(Suppl 1): 51-8
• 19 Sharma C, Al Kaabi JM, Nurulain SM, Goyal SN, Kamal MA, Ojha S. Polypharmacological properties and therapeutic potential of β-caryophyllene: a dietary phytocannabinoid of pharmaceutical promise. Curr Pharm Des 2016; 22(21): 3237-64
• 20 Shrimali RK, Irons RD, Carlson BA, Sano Y, Gladyshev VN, Park JM, Hatfield DL. Selenoproteins mediate T cell immunity through an antioxidant mechanism. J Biol Chem 2008; 283(29): 20181-5
• 21 Singer O, Cigler T, Moore AB, Levine AB, Do HT, Mandl LA. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms. Breast J 2014; 20(2): 174-9
• 22 Singh S, Cuzick J, Mesher D, Richmond B, Howell A. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Res Treat 2012; 132(2): 625-9
• 23 Stone P, Richardson A, Ream E, Smith AG, Kerr DJ, Kearney N. Cancer-related fatigue: inevitable, unimportant and untreatable? Results of a multi-centre patient survey. Ann Oncol 2000; 11(8): 971-5
• 24 Visovsky C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 2007; 11(6): 901-13